Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Limited treatment options are available for stage IIIB/IV non‐small cell lung cancer (NSCLC). Nivolumab, a programmed cell death‐1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. The present study investigated the effectiveness and safety of nivolumab...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Sci
Main Authors: Hida, Toyoaki, Nishio, Makoto, Nogami, Naoyuki, Ohe, Yuichiro, Nokihara, Hiroshi, Sakai, Hiroshi, Satouchi, Miyako, Nakagawa, Kazuhiko, Takenoyama, Mitsuhiro, Isobe, Hiroshi, Fujita, Shiro, Tanaka, Hiroshi, Minato, Koichi, Takahashi, Toshiaki, Maemondo, Makoto, Takeda, Koji, Saka, Hideo, Goto, Koichi, Atagi, Shinji, Hirashima, Tomonori, Sumiyoshi, Naoki, Tamura, Tomohide
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2017
נושאים:
Original Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5448646/
https://ncbi.nlm.nih.gov/pubmed/28266091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13225
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים